SCHEMBL993677

SCHEMBL993677

OC(F)(F)C(F)C(Cl)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL7562031 0.84 FFAR3 (0.33)
SCHEMBL115406 0.74
SCHEMBL2465562 0.72
SCHEMBL181476 0.72
SCHEMBL666082 0.72 LMNA (0.33)
SCHEMBL505749 0.70
SCHEMBL28815631 0.69
SCHEMBL27990990 0.67
SCHEMBL129262 0.67
SCHEMBL15700155 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240158374-A1 Pyrazolopyridine Derivatives and Uses thereof NOVARTIS AG (CH) 2024-05-16 US disclosed
EP-4308562-A1 PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF Novartis AG (CH) 2024-01-24 EP disclosed
WO-2024015924-A2 HYBRID OLIGONUCLEOTIDES ENTRADA THERAPEUTICS, INC. (US) 2024-01-18 WO disclosed
US-20240000890-A1 NEURAL REGENERATION WITH SYNTHETIC PROTEIN ADMINISTRATION Retinal Solutions, LLC (US) 2024-01-04 US disclosed
US-11787785-B2 Pyrazolopyridine derivatives and uses thereof NOVARTIS AG (CH) 2023-10-17 US disclosed
CN-116802182-A Pyrazolopyridine derivatives and uses thereof 诺华股份有限公司 2023-09-22 CN disclosed
US-20230126239-A1 NORRIN REGULATION OF PLASMALEMMA VESICLE-ASSOCIATED PROTEIN AND USE TO TREAT MACULAR DEGENERATION Retinal Solutions, LLC (US) 2023-04-27 US disclosed
US-20230108325-A1 Pyrazolopyridine Derivatives and Uses thereof NOVARTIS AG (CH) 2023-04-06 US disclosed
EP-4117708-A1 NORRIN REGULATION OF PLASMALEMMA VESICLE-ASSOCIATED PROTEIN AND USE TO TREAT MACULAR DEGENERATION Retinal Solutions, LLC (US) 2023-01-18 EP disclosed
WO-2021183407-A1 NORRIN REGULATION OF PLASMALEMMA VESICLE-ASSOCIATED PROTEIN AND USE TO TREAT MACULAR DEGENERATION Retinal Solutions, LLC (US) 2021-09-16 WO disclosed
US-7262268-B2 Lipopeptide stereoisomers, methods for preparing same, and useful intermediates CUBIST PHARMACEUTICALS, INC. (US) 2007-08-28 US disclosed
US-20060223983-A1 Lipopeptide stereoisomers, methods for preparing same and useful intermediates CUBIST PHARMACEUTICALS, INC. 2006-10-05 US disclosed
EP-1423137-A4 LIPOPEPTIDE STEREOISOMERS, METHODS FOR PREPARING SAME, AND USEFUL INTERMEDIATES CUBIST PHARM INC (US) 2005-11-30 EP disclosed
EP-1423137-A2 LIPOPEPTIDE STEREOISOMERS, METHODS FOR PREPARING SAME, AND USEFUL INTERMEDIATES Cubist Pharmaceuticals, Inc. (US) 2004-06-02 EP disclosed
US-20030096948-A1 Lipopeptide stereoisomers, methods for preparing same, and useful intermediates ADOLOR CORPORATION 2003-05-22 US disclosed
WO-2003017924-A2 LIPOPEPTIDE STEREOISOMERS, METHODS FOR PREPARING SAME, AND USEFUL INTERMEDIATES CUBIST PHARMACEUTICALS, INC. (US) 2003-03-06 WO disclosed
EP-0842195-A1 PEPTIDE INHIBITORS OF FIBRONECTINE ZENECA LIMITED (GB) 1998-05-20 EP disclosed
WO-1997002289-A1 PEPTIDE INHIBITORS OF FIBRONECTINE ZENECA LIMITED (GB) 1997-01-23 WO disclosed
EP-0285562-B1 SYNTHETIC RESIN CIBA-GEIGY AG (CH) 1993-04-28 EP disclosed
EP-0285562-A2 Synthetic resin CIBA-GEIGY AG (CH) 1988-10-05 EP disclosed